WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) announced that the German Federal Institute for Drugs and Medical Devices approved the Phase I trial with the MEK inhibitor WX-554. The trial is a first-in-man-trial in healthy volunteers and will be conducted at a single site in Germany. With the first dose in man, the second milestone payment of EUR 5 million agreed in the strategic alliance with UCB Pharma S.A. will become due.

 Read the release.

Advertisements